The $0 benefit needs a new prior approval and still excludes weight loss use. Enrollment for about 1.6 million US associates runs through Nov. 6.
Recap by typeshit. Full story at Medical Daily.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
Researchers also saw fewer COPD flare-ups, though they say trials built around breathing outcomes are the next step before drawing firm conclusions.
Cyprus Mail reports that Mounjaro is being added to Gesy coverage for people with diabetes and for adults with obesity.
Loading…